PRN: ReportsnReports - Middleware Messaging Market, HIV Market Outlook & Next-Generation Protein and Peptide Therapeutics
ReportsnReports - Middleware Messaging Market, HIV Market Outlook & Next-Generation Protein and Peptide Therapeutics
DALLAS, September 5, 2011 /PRNewswire/ --
ReportsnReports announces it will carry market research intelligence on Middleware Messaging Market, HIV Market Outlook & Next-Generation Protein and Peptide Therapeutics in its store
Worldwide mission critical middleware messaging is poised to achieve significant growth as this software is used to achieve transport of information between business platforms and applications. Â The markets are expanding in response to demand for real time computing providing productivity improvements across the board and improvements in efficiency of Internet transactions. Â IBM WebSphereMQ is the defacto message transport standard. Â WebSphereMQ becomes a significant aspect of SOA because it is so good at managing decoupled messages. Â WebSphere MQ is at the center of the IBM middleware offerings because it provides the structure for the bus. Â WebShpere MQ is the Â wrapper for SOAP and JMS messages even when it is not the most visible transport messaging system. Â All mission critical messaging form all vendors implement SOA. Â Market growth is anticipated to be based on implementation of SOA. Â SOA process components support enterprise change. Â Software forms the b! asis of change.
Get Table of Contents and complete report on Middleware Messaging Market.
In terms of sales, the US dominated the global HIV market, accounting for just over 50% of sales in 2010. Collectively, the leading pharmaceutical markets of the EU were the second largest HIV market with a market share of just over 33%. The countries with very high endemicity of HIV actually only account for very small market shares.
The current market for HIV treatment is dominated by once-daily regimens. There is a strong trend towards regimen simplification and reduced pill burden, which has resulted in the rapid penetration of several once daily treatment options. To this end Gilead is developing a Quad Pill which contains four active ingredients the first such product.
Gilead was the leading company in the 2010 recording sales of over $6bn at a Y-o-Y growth of over 13%. Gilead's performance in 2010 was very strong, capturing over 35% of the global HIV market. This strong performance was largely due to the company's leading NRTI product, Atripla which posted 2010 sales of $3bn at a Y-o-Y growth of 22.9%.
Get Table of Contents and complete report on the HIV Market.
The recent sales performance of monoclonal antibody therapeutics, including three launched antibody fragments, has fuelled further innovation in antibody-derived therapeutics. Along with the development of those agents, progress has been made with novel binding proteins and peptides that avoid some of the drawbacks associated with antibodies.
Many collaborations involving large pharma companies are focused on the development of immunoconjugates featuring stable linker systems between an antibody or an antibody fragment and a highly potent drug for use in cancer therapy. These products target well-characterized tumor antigens.
Protein binders based on a scaffold other than that of an antibody have entered clinical trials, and one has recently been approved by the FDA. Agents based on human proteins offer many potential advantages over antibody-derived binders, including absent or lower immunogenicity.:
Get Table of Contents and complete report on Next-Generation Protein and Peptide Therapeutics Market.
Other new and latest market research on ReportsnReports.com:
ReportsnReports is an online market research library of 125,000+ reports and in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.
'Like Us'Â on Facebook:http://www.facebook.com/pages/ReportsnReports/191441427571689